Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

The Trust Test

Roche Basel Switzerland

Roche’s Soliris rival Enspryng bags FDA approval

Drug is second to be approved for the treatment of NMOSD

AstraZeneca AZ

AZ inks deal with EU for 400 million doses of COVID-19 vaccine

Doses will be available to all EU member states at no profit during pandemic

- PMLiVE

Public Health England to be axed over coronavirus response

Report from The Sunday Telegraph details plans to replace agency

- PMLiVE

Has AI been the key to tackling the COVID-19 pandemic?

By Nikolas Kairinos

- PMLiVE

COVID-19 vaccine approval unlikely before November, says US NIH director

US National Institutes of Health Director Francis Collins cautioned against unrealistic timelines

- PMLiVE

UK agrees on COVID-19 vaccine deals with J&J and Novavax

Initial agreement secures 90 million doses

- PMLiVE

Calliditas bets on PBC drug in Genkyotex buyout

Calliditas will acquire 62.7% of company for an initial €20.3m

- PMLiVE

Speed kills

From testing to reopening to vetting scientific articles, we have lost track of time

Unleashing the Potential of Multichannel Digital Strategies in Healthcare

Christine Jacob, Founder and Managing Director of Digi-Bridges, talks about the future of mobile and digital health, including exciting technologies such as VR and AR. We also touch on a wide variety...

Impetus Digital

- PMLiVE

It’s been ten magical years at Lucid Group for Emma Cox

August marks a special work anniversary for Emma Cox who is celebrating 10 years at Lucid Group!Over the past decade, Emma has demonstrated resilience, tenacity and grit with a disarming...

Lucid Group Communications Limited

- PMLiVE

AbbVie, Roche’s Venclyxto combo reduces risk of death in first-line AML

Data from the trial has been published in the New England Journal of Medicine

- PMLiVE

FDA approves Sarepta rival NS Pharma’s Duchenne drug

Drug approved for patients with exon 53 mutation

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links